Genentech settles Rituxan whisteblower suit for $20M

Genentech Inc. will pay $20 million to settle a whistleblower lawsuit around off-label marketing of the cancer-fighting drug Rituxan.
The settlement, completed last month and first reported by Drug Industry Daily, will net $5.7 million for John Underwood, who was a senior manager of sales development from the start of Genentech’s oncology franchise in 1997.